Business profile & competitive position
Agilent Technologies, Inc. operates in Healthcare under the Medical – Diagnostics & Research industry group. The company sells application-focused solutions for the life sciences, diagnostics, and applied markets: instruments, software, services, and consumables across the full laboratory workflow. Following a November 2024 reorganization, Agilent now reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Distribution is primarily direct, with additional sales through distributors, resellers, manufacturers' representatives, and e-commerce channels.
On the numbers, Agilent carries a net margin of 19.5% and ROE of 20.5%. Those figures are comfortably above what commodity-equipment vendors typically produce, suggesting pricing power tied to application-specific intellectual property, consumables pull-through, and multi-year service contracts. A 20.5% ROE also indicates that reinvested capital earns a return well above the cost of capital for this sector, which is consistent with an installed-base model where customers face switching costs once an Agilent workflow is embedded in a regulated lab. That said, margin alone does not define a moat; Agilent competes with Thermo Fisher, Waters, Danaher, and others whose portfolios have similar breadth, so the 19.5% margin should be read as evidence of strong execution rather than an unassailable competitive fortress.
Financial posture
Agilent's current market capitalization is $48.5 billion, with the stock trading at $171.99 and a P/E ratio of 33.8. A P/E in the low-thirties for a diagnostics and life-sciences tools company implies the market is already pricing in above-average earnings growth and margin resilience. The 19.5% net margin supports that premium valuation, but it also leaves limited room for multiple expansion if top-line growth slows or if capital allocation disappoints.
Profitability metrics are solid: 19.5% net margin and 20.5% ROE are near the upper range for this industrial subsector. Volatility is slightly above average with a beta of 1.24, meaning the stock has historically moved about 24% more than the overall market during broad swings. The current RSI sits at 50.6 and the 50-day exponential moving average is $165.24, so price is relatively close to a neutral short-term technical level. There is no debt figure highlighted in the current snapshot, so leverage cannot be scored here; the financial impression is one of a high-quality, premium-valued instrument and consumables company whose multiples assume continued execution.
Strategic priorities & outlook
Agilent's most recent 10-K filing points to a deliberate shift into three reportable segments to drive a market-focused, customer-centric strategy. The reorganization is not a footnote: it is the framework through which product development, go-to-market effort, and investor reporting are now aligned.
Three operational priorities stand out. First, the company is expanding the liquid chromatography application space with new columns, new services, and ongoing enhancements to instruments and software. Second, it wants to keep improving mass spectrometry capabilities around performance, sensitivity, precision, robustness, ease of use, and onboard intelligence. Third, it is advancing software and service solutions to support what it calls a digitally connected smart lab, using data analytics, artificial intelligence, and robotics to integrate otherwise siloed lab workflows. As of October 31, 2025, Agilent employed approximately 18,100 people worldwide, with the largest contingent, about 7,400 employees, inside Agilent CrossLab and 6,300 within Life Sciences and Diagnostics Markets. Manufacturing and R&D sites are spread across the United States, Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the United Kingdom, all supported by centralized order fulfillment and a shared global infrastructure covering finance, IT, legal, procurement, workplace, and HR.
Macro & geopolitical exposure
As a Healthcare / Medical – Diagnostics & Research company with global manufacturing and a large China presence, Agilent is exposed to several recurring macro themes. Life-sciences and diagnostic instrument demand is cyclical with biopharma capital spending, academic research budgets, and diagnostic procedure volumes. A deterioration in biopharma funding or hospital capital-expenditure plans would weigh on instrument replacement cycles.
Because Agilent makes regulated laboratory equipment, product approval and quality requirements from the U.S. FDA, China's NMPA, and European regulatory bodies create compliance costs and can delay launches. Trade policy is another factor: with R&D and manufacturing in the United States, China, Europe, and Asia, tariffs or export controls on high-end analytical instruments can affect both cost structures and market access. Currency is a persistent consideration for a company that books revenue across dollars, euros, yen, yuan, and other currencies. Supply-chain concentration in certain electronic components, specialty optics, and precision manufacturing also remains a sector-wide risk, even when centralized order fulfillment is in place.
Recent developments
The most concrete news item is the November 23, 2026 after-close earnings announcement, which Agilent confirmed on October 29, 2026 via BusinessWire. The market's real expectation heading into that report is a fourth-quarter fiscal 2026 EPS of $1.73. Beyond the earnings calendar, the October 27–29 window saw several fund portfolio reviews from SeekingAlpha referencing Agilent as a mid-cap growth holding, including the Carillon Scout Mid Cap Fund Q3 2026 Portfolio Review on October 27, the Parnassus Mid Cap Fund Q3 2026 Portfolio Review on October 28, and the Parnassus Mid Cap Growth Fund Q3 2026 Performance Review on October 29. These are disclosures of existing positions or performance attributions rather than new recommendations, but they confirm that Agilent remains on the radar of active mid-cap growth managers as the company approaches its quarterly report.
Earnings behavior & post-earnings drift
Agilent's earnings track record over the last eight reported quarters is strong on the surface: the company beat estimates in six of those eight quarters for an 86% beat rate, with an average earnings surprise of 3%. The average five-day post-earnings drift is classified as "up" at 2.44%. However, the real lesson for traders and analysts is that the drift is not a clean function of whether Agilent beats or misses.
Looking at the last four quarters exposes the dispersion. On August 26, 2026 Agilent reported $1.62 versus an estimate of $1.49, an 8.7% surprise that should have been strongly rewarded; the stock gained 1.68% the next day but gave back 2.38% over the following five days. The May 27, 2026 quarter is an outlier: EPS of $1.49 versus $1.41, only a 5.7% beat, yet the stock surged 16.87% the next session and tacked on 18.61% over five days. That single quarter likely accounts for much of the positive average drift figure. By contrast, the February 25, 2026 quarter saw a small $1.36 versus $1.37 miss, and the stock fell 3.01% the next day and 3.35% over the next five sessions. Even the November 24, 2025 quarter, a razor-thin 0.4% beat on $1.59 versus $1.58431 in estimated EPS, produced a 2.34% next-day gain but a 3.12% five-day decline.
This pattern matters for how one interprets "beat rate." A 6/8 beat rate and 3% average surprise say one thing about execution; the five-day drift data says the market's real expectation and the unofficial consensus are already causing much of the good news to be priced in, or are being offset by guidance, macro commentary, or sector rotation. The average 2.44% upward drift is therefore better understood as the result of one extraordinary quarter plus smaller contributions elsewhere, rather than a reliable post-earnings escalator.
Frequently Asked Questions
What does the 86% beat rate tell us about Agilent's earnings consistency?
Over the last eight quarters Agilent beat expectations six times, producing an 86% beat rate with an average earnings surprise of 3%. That indicates management generally guides conservatively and operations have delivered modestly ahead of plan, but the figure does not guarantee future outcomes or predict the stock's direction in any single quarter.
How should the 33.8 P/E and 20.5% ROE be interpreted together?
A 33.8 P/E shows the market is paying a premium multiple, while a 20.5% ROE shows Agilent does earn a high return on equity. The combination suggests investors are pricing in continued strong returns, but it also means the stock is not cheap in absolute terms; earnings growth and margin maintenance become important to justifying the valuation.
Why doesn't Agilent stock always go up after an earnings beat?
Although Agilent has beaten estimates in six of the last eight quarters, the five-day post-earnings drift is volatile. For example, the August 26, 2026 quarter beat by 8.7% yet the stock fell 2.38% over the following five days. That disconnect shows that guidance, sector sentiment, and pre-report positioning often matter more than the headline beat alone.
For a deeper look at how institutional analysts are modeling Agilent's revenue trajectory, margin path, and risk factors, the full institutional research verdict on the ticker provides more granular detail than any single summary can capture.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-08-26 | $1.62 | $1.49 | +8.7% | +1.68% | -2.38% |
| 2026-05-27 | $1.49 | $1.41 | +5.7% | +16.87% | +18.61% |
| 2026-02-25 | $1.36 | $1.37 | -0.7% | -3.01% | -3.35% |
| 2025-11-24 | $1.59 | $1.58431 | +0.4% | +2.34% | -3.12% |
| 2025-08-27 | $1.37 | $1.37 | 0% | - | - |
| 2025-05-28 | $1.31 | $1.26 | +4% | - | - |
Previous A editions
Get the institutional verdict on A
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the A verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.